Elekta Unity Clinical Indications Bibliography
This bibliography highlights clinical publications that demonstrate the clinical implementation and benefits of Elekta Unity MR-Linac for a variety of patients and indications. Articles are categorized by anatomy and shown in descending order of publication date.
Abdomen
Gating and intrafraction drift correction on a 1.5 T MR-Linac: clinical dosimetric benefits for upper abdominal tumors.
Radiother Oncol. 2023;189:109932. Grimbergen G; Hackett SL; van Ommen F; van Lier ALHMW; Borman PTS; Meijers LTC; de Groot-van Breugel EN; de Boer JCJ; Raaymakers BW; Intven MPW; Meijer GJ. doi: 10.1016/j.radonc.2023.109932.
Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac.
Front Oncol. 2023;13. Eijkelenkamp H; Grimbergen G; Daamen LA; Heerkens HD; van de Ven S; Mook S; Meijer GJ; Molenaar IQ; van Santvoort HC; Paulson E; Erickson BA; Verkooijen HM; Hall WA; Intven MPW. doi: 10.3389/fonc.2023.1040673.
Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases.
Front Oncol. 2022;12:1095633. Uder L; Nachbar M; Butzer S; Boldt J; Baumeister S; Bitzer M; Königsrainer A; Seufferlein T; Hoffmann R; Gatidis S; Nikolaou K; Zips D; Thorwarth D; Gani C; Boeke S. doi: 10.3389/fonc.2022.1095633.
Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system.
Phys Imaging Radiat Oncol. 2022;24:88-94. Tringale KR; Tyagi N; Marsha Reyngold; Romesser PB; Wu A; O'Reilly EM; Varghese AM; Godoy Scripes P; Khalil DN; Park W; Yu K; Crane CH. doi: 10.1016/j.phro.2022.10.003.
A case study of DIBH to spare abdominal organs at risk for renal cell carcinoma MR-guided radiotherapy.
Med Dosim. 2022;47:e19-e23. Yorio SD; Lenards N; Hunzeker A. doi: 10.1016/j.meddos.2022.01.002.
First multicentre experience of SABR for lymph node and liver oligometastatic disease on the Unity MR-Linac.
Tech Innov Patient Support Radiat Oncol. 2022;22:50-54. Janssen TM; Aitken K; Alongi F; Barry A; Bernchou U; Boeke S; Hall WA; Hosni A; Kroon PS; Nachbar M; Saeed H; Jürgenliemk-Schulz IM; Schytte T; Verkooijen HM; Nowee ME. doi: 10.1016/j.tipsro.2022.04.005.
Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac.
Acta Oncol. 2022;61:111-115. Daamen LA; de Mol van Otterloo SR; van Goor IWJM; Eijkelenkamp H; Erickson BA; Hall WA; Heerkens HD; Meijer GJ; Molenaar IQ; van Santvoort HC; Verkooijen HM; Intven MPW. doi: 10.1080/0284186X.2021.2012593.
MRI-Guided Online Adaptive Stereotactic Body Radiation Therapy of Liver and Pancreas Tumors on an MR-Linac System.
Cancers (Basel). 2022;14:716. Stanescu T; Shessel A; Carpino-Rocca C; Taylor E; Semeniuk O; Li W; Barry A; Lukovic J; Dawson L; Hosni A. doi: 10.3390/cancers14030716.
Technical feasibility and clinical evaluation of 4D-MRI guided liver SBRT on the MR-linac.
Radiother Oncol. 2022;167:285-291. van de Lindt A; Nowee B; Janssen T; Schneider C; Remeijer P; van Pelt VWJ; Betgen A; Jansen EPM; Sonke JJ. doi: 10.1016/j.radonc.2022.01.009.
MR-Guided Radiotherapy for Liver Malignancies.
Front Oncol. 2021;11:616027. Boldrini L; Corradini S; Gani C; Henke L; Hosni A; Romano A; Dawson L. doi: 10.3389/fonc.2021.616027.
Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma.
Front Oncol. 2021;11:634830. Keller B; Bruynzeel AME; Tang C; Swaminath A; Kerkmeijer L; Chu W. doi: 10.3389/fonc.2021.634830.
Feasibility of ablative stereotactic body radiation therapy of pancreas cancer patients on a 1.5 Tesla magnetic resonance-linac system using abdominal compression.
Phys Imaging Radiat Oncol. 2021;19:53-59. Tyagi N; Liang J; Burleson S; Subashi E; Godoy Scripes P; Tringale KR; Romesser PB; Reyngold M; Crane CH. doi: 10.1016/j.phro.2021.07.006.
Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac - Feasibility, workflow data and patient acceptance.
Clin Transl Radiat Oncol. 2021;26:55-61. Gani C; Boeke S; McNair H; Ehlers J; Nachbar M; Monnich D; Stolte A; Boldt J; Marks C; Winter J; Kunzel LA; Gatidis S; Bitzer M; Thorwarth D; Zips D. doi: 10.1016/j.ctro.2020.11.014.
Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.
Int J Radiat Oncol Biol Phys. 2021;111:867-875. Christodouleas JP; Blezer ELA; Akhiat H; Brown K; Choudhury A; Eggert D; Erickson BA; Daamen LA; Faivre-Finn C; Fuller CD; Goldwein J; Hafeez S; Hall E; Harrington KJ; van der Heide UA; Huddart RA; Intven MPW; Kirby AM; Lalondrelle S; McCann C; Minsky BD; Mook S; Nowee ME; Oelfke U; Orrling K; Philippens MEP; Sahgal A; Schultz CJ; Tersteeg RJHA; Tijssen RHN; Tree AC; van Triest B; Tseng CL; Hall WA; Verkooijen HM; de_Mol_van_Otterloo SR. doi: 10.1016/j.ijrobp.2021.07.003.
Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions.
Front Oncol. 2021;11:628155. Hall WA; Small C; Paulson E; Koay EJ; Crane C; Intven M; Daamen LA; Meijer GJ; Heerkens HD; Bassetti M; Rosenberg SA; Aitken K; Myrehaug S; Dawson LA; Lee P; Gani C; Chuong MD; Parikh PJ; Erickson BA. doi: 10.3389/fonc.2021.628155.
Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases.
Cancers (Basel). 2021;13:1336. Romesser PB; Tyagi N; Crane CH. doi: 10.3390/cancers13071636.
Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach.
Pract Radiat Oncol. 2020;10:e495-e507. Koay EJ; Hanania AN; Hall WA; Taniguchi CM; Rebueno N; Myrehaug S; Aitken KL; Dawson LA; Crane CH; Herman JM; Erickson B. doi: 10.1016/j.prro.2020.01.012.
Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac.
PLoS One. 2020;15:e0236570. Hall WA; Straza MW; Chen X; Mickevicius N; Erickson B; Schultz C; Awan M; Ahunbay E; Li XA; Paulson ES. doi: 10.1371/journal.pone.0236570.
4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience.
Clin Transl Radiat Oncol. 2020;23:72-79. Paulson ES; Ahunbay E; Chen X; Mickevicius NJ; Chen GP; Schultz C; Erickson B; Straza M; Hall WA; Li XA. doi: 10.1016/j.ctro.2020.05.002.
Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac
Front Oncol. 2023;13:1040673. Eijkelenkamp H; Grimbergen G; Daamen L; Heerkens H; van de Ven S; Mook S; Meijer G; Molenaar I; van Santvoort H; Paulson E; Erickson B; Verkooijen H; Hall W; Intven M. doi: 10.3389/fonc.2023.1040673.
The Use of MR-Guided Radiation Therapy for Liver Cancer.
Semin Radiat Oncol. 2024;34:36-44. Prime S; Schiff JP; Hosni A; Stanescu T; Dawson LA; Henke LE. doi: 10.1016/j.semradonc.2023.10.006.
The Use of MR-Guided Radiation Therapy for Pancreatic Cancer.
Semin Radiat Oncol. 2024;34:23-35. Daamen LA; Parikh PJ; Hall WA. doi: 10.1016/j.semradonc.2023.10.002.
Gating and intrafraction drift correction on a 1.5 T MR-Linac: clinical dosimetric benefits for upper abdominal tumors.
Radiother Oncol. 2023;:109932. Grimbergen G; Hackett SL; van Ommen F; L H M W van Lier van Lier A; Borman PTS; Meijers LTC; de Groot-van Breugel EN; de Boer JCJ; Raaymakers BW; Intven MPW; Meijer GJ. doi: 10.1016/j.radonc.2023.109932.
Bladder
Feasibility of tumour-focused adaptive radiotherapy for bladder cancer on the MR-linac.
Clin Transl Radiat Oncol. 2022;35:27-32. Mitchell A; Ingle M; Smith G; Chick J; Diamantopoulos S; Goodwin E; Herbert T; Huddart R; McNair H; Oelfke U; Nill S; Dunlop A; Hafeez S. doi: 10.1016/j.ctro.2022.04.008.
MR-Guided Adaptive Radiotherapy for Bladder Cancer.
Front Oncol. 2021;11:637591. Hijab A; Tocco B; Hanson I; Meijer H; Nyborg CJ; Bertelsen AS; Smeenk RJ; Smith G; Michalski J; Baumann BC; Hafeez S. doi: 10.3389/fonc.2021.637591.
Comparison of Library of Plans with two daily adaptive strategies for whole bladder radiotherapy.
Phys Imaging Radiat Oncol. 2021;20:82-87. den Boer D; den Hartogh MD; Kotte ANTJ; van der Voort van Zyp JRN; Noteboom JL; Bol GH; Willigenburg T; Werensteijn-Honingh AM; Jurgenliemk-Schulz IM; van Lier ALHMW; Kroon PS. doi: 10.1016/j.phro.2021.11.002.
Image-guided Adaptive Radiotherapy for Bladder Cancer.
Clin Oncol (R Coll Radiol). 2021;33:350-368. Kong V; Hansen VN; Hafeez S. doi: 10.1016/j.clon.2021.03.023.
Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer.
Clin Transl Radiat Oncol. 2020;25:46-51. Hunt A; Hanson I; Dunlop A; Barnes H; Bower L; Chick J; Cruickshank C; Hall E; Herbert T; Lawes R; McQuaid D; McNair H; Mitchell A; Mohajer J; Morgan T; Oelfke U; Smith G; Nill S; Huddart R; Hafeez S. doi: 10.1016/j.ctro.2020.09.002.
Brain and Spine
Diffusion-weighted imaging on an MRI-linear accelerator to identify adversely prognostic tumour regions in glioblastoma during chemoradiation.
Radiother Oncol. 2023;188:109873. Lawrence LSP; Chan RW; Chen H; Stewart J; Ruschin M; Theriault A; Myrehaug S; Detsky J; Maralani PJ; Tseng CL; Soliman H; Jane Lim-Fat M; Das S; Stanisz GJ; Sahgal A; Lau AZ. doi: 10.1016/j.radonc.2023.109873.
An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases.
Clin Transl Radiat Oncol. 2023;40:100602. Ding S; Liu B; Zheng S; Wang D; Liu M; Liu H; Zhang P; Peng K; He H; Zhou R; Guo J; Qiu B; Huang X; Liu H. doi: 10.1016/j.ctro.2023.100602.
Empirical planning target volume modeling for high precision MRI guided intracranial radiotherapy.
Clin Transl Radiat Oncol. 2023;39:100582-100582. Stewart J; Sahgal A; Zadeh MM; Moazen B; Jabehdar Maralani P; Breen S; Lau A; Binda S; Keller B; Husain Z; Myrehaug S; Detsky J; Soliman H; Tseng CL; Ruschin M. doi: 10.1016/j.ctro.2023.100582.
Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC: a prospective serial imaging study.
J Neurooncol. 2022;156:569-577. Tan H; Stewart J; Ruschin M; Wang MH; Myrehaug S; Tseng CL; Detsky J; Husain Z; Chen H; Sahgal A; Soliman H. doi: 10.1007/s11060-021-03938-w.
High grade glioma radiation therapy on a high field 1.5 Tesla MR-Linac - workflow and initial experience with daily adapt-to-position (ATP) MR guidance: A first report.
Front Oncol. 2022;12:1060098. Tseng CL; Chen H; Stewart J; Lau AZ; Chan RW; Lawrence LSP; Myrehaug S; Soliman H; Detsky J; Lim-Fat MJ; Lipsman N; Das S; Heyn C; Maralani PJ; Binda S; Perry J; Keller B; Stanisz GJ; Ruschin M; Sahgal A. doi: 10.3389/fonc.2022.1060098.
Accuracy and precision of apparent diffusion coefficient measurements on a 1.5 T MR-Linac in central nervous system tumour patients.
Radiother Oncol. 2021;164:155-162. Lawrence LSP; Chan RW; Chen H; Keller B; Stewart J; Ruschin M; Chugh B; Campbell M; Theriault A; Stanisz GJ; MacKenzie S; Myrehaug S; Detsky J; Maralani PJ; Tseng CL; Czarnota GJ; Sahgal A; Lau AZ. doi: 10.1016/j.radonc.2021.09.020.
Glioma consensus contouring recommendations from a MR-Linac International Consortium Research Group and evaluation of a CT-MRI and MRI-only workflow.
J Neurooncol. 2020;149:305-314. Tseng CL; Stewart J; Whitfield G; Verhoeff JJC; Bovi J; Soliman H; Chung C; Myrehaug S; Campbell M; Atenafu EG; Heyn C; Das S; Perry J; Ruschin M; Sahgal A. doi: 10.1007/s11060-020-03605-6.
Feasibility of spinal stereotactic body radiotherapy in Elekta Unity MR-Linac.
J Radiosurg SBRT. 2020;7:127-134. Han EY; Aima M; Hughes N; Briere TM; Yeboa DN; Castillo P; Wang J; Yang J; Vedam S.
First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment.
Phys Med Biol. 2017;62:L41-L50. Raaymakers BW; Jürgenliemk-Schulz IM; Bol GH; Glitzner M; Kotte ANTJ; van Asselen B; de Boer JCJ; Bluemink JJ; Hackett SL; Moerland MA; Woodings SJ; Wolthaus JWH; van Zijp HM; Philippens MEP; Tijssen R; Kok JGM; de Groot-van Breugel EN; Kiekebosch I; Meijers LTC; Nomden CN; Sikkes GG; Doornaert PAH; Eppinga WSC; Kasperts N; Kerkmeijer LGW; Tersteeg JHA; Brown KJ; Pais B; Woodhead P; Lagendijk JJW. doi: 10.1088/1361-6560/aa9517.
MR-guided radiation therapy: transformative technology and its role in the central nervous system.
Neuro Oncol. 2017;19:ii16-ii29. Cao Y; Tseng CL; Balter JM; Teng F; Parmar HA; Sahgal A. doi: 10.1093/neuonc/nox006.
Adoption of Hybrid MRI-Linac Systems for the Treatment of Brain Tumors: A Systematic Review of the Current Literature Regarding Clinical and Technical Features.
Technol Cancer Res Treat. 2023;22:15330338231199286. Guerini AE; Nici S; Magrini SM; Riga S; Toraci C; Pegurri L; Facheris G; Cozzaglio C; Farina D; Liserre R; Gasparotti R; Ravanelli M; Rondi P; Spiazzi L; Buglione M. doi: 10.1177/15330338231199286.
Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon.
Neuro Oncol. 2024;26:S3-S16. Tseng CL; Zeng KL; Mellon EA; Soltys SG; Ruschin M; Lau AZ; Lutsik NS; Chan RW; Detsky J; Stewart J; Maralani PJ; Sahgal A. doi: 10.1093/neuonc/noad258.
Breast
Adaptive radiotherapy for breast cancer.
Clin Transl Radiat Oncol. 2023;39:100564. De-Colle C; Kirby A; Russell N; Shaitelman SF; Currey A; Donovan E; Hahn E; Han K; Anandadas CN; Mahmood F; Lorenzen EL; van den Bongard D; Groot Koerkamp ML; Houweling AC; Nachbar M; Thorwarth D; Zips D. doi: 10.1016/j.ctro.2022.100564.
Estimation of secondary cancer projected risk after partial breast irradiation at the 1.5 T MR-linac.
Strahlenther Onkol. 2022;198:622-629. De-Colle C; Dohm O; Mönnich D; Nachbar M; Weidner N; Heinrich V; Boeke S; Gani C; Zips D; Thorwarth D. doi: 10.1007/s00066-022-01930-5.
Use of magnetic resonance image-guided radiotherapy for breast cancer: a scoping review.
J Med Radiat Sci. 2022;69:122-133. Berlangieri A; Elliott S; Wasiak J; Chao M; Foroudi F. doi: 10.1002/jmrs.545.
Consensus on Contouring Primary Breast Tumors on MRI in the Setting of Neoadjuvant Partial Breast Irradiation in Trials.
Pract Radiat Oncol. 2020;10:e466-e474. Vasmel JE; Groot Koerkamp ML; Kirby AM; Russell NS; Shaitelman SF; Vesprini D; Anandadas CN; Currey A; Keller BM; Braunstein LZ; Han K; Kotte ANTJ; de Waard SN; Philippens MEP; Houweling AC; Verkooijen HM; van den Bongard HJGD. doi: 10.1016/j.prro.2020.03.011.
Optimizing MR-Guided Radiotherapy for Breast Cancer Patients.
Front Oncol. 2020;10:1107. Groot Koerkamp ML; Vasmel JE; Russell NS; Shaitelman SF; Anandadas CN; Currey A; Vesprini D; Keller BM; De-Colle C; Han K; Braunstein LZ; Mahmood F; Lorenzen EL; Philippens MEP; Verkooijen HM; Lagendijk JJW; Houweling AC; van den Bongard HJGD; Kirby AM. doi: 10.3389/fonc.2020.01107.
Partial breast irradiation with the 1.5 T MR-Linac: First patient treatment and analysis of electron return and stream effects.
Radiother Oncol. 2020;145:30-35. Nachbar M; Mönnich D; Boeke S; Gani C; Weidner N; Heinrich V; Lo Russo M; Livi L; Winter J; Tsitsekidis S; Dohm O; Thorwarth D; Zips D; De-Colle C. doi: 10.1016/j.radonc.2019.11.025.
GYN
MRI guided High Dose Rate Gynecological Brachytherapy using an MR-Linac as an MR simulator: A Single Institutional Experience.
Pract Radiat Oncol. 2023;23. Massock W; Kim Y; Dresner MA; WenqingSun; Caster J; Adams Q; Jespersen J; St-Aubin J. doi: 10.1016/j.prro.2023.08.003.
The utility of 1.5 tesla MR-guided adaptive stereotactic body radiotherapy for recurrent ovarian tumor - Case reports and review of the literature.
Int J Surg Case Rep. 2022;99:107696. Yavas G; Kuscu UE; Ayhan A; Yavas C; Onal C. doi: 10.1016/j.ijscr.2022.107696.
Clinical Implementation and Initial Experience With a 1.5 Tesla MR-Linac for MR-Guided Radiation Therapy for Gynecologic Cancer: An R-IDEAL Stage 1 and 2a First in Humans Feasibility Study of New Technology Implementation.
Pract Radiat Oncol. 2022;12:e296-e305. Lakomy DS; Yang J; Vedam S; Wang J; Lee B; Sobremonte A; Castillo P; Hughes N; Mohammedsaid M; Jhingran A; Klopp AH; Choi S; Fuller CD; Lin LL. doi: 10.1016/j.prro.2022.03.002.
Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for Gynecological Cancers.
Front Oncol. 2021;11:628131. Portelance L; Corradini S; Erickson B; Lalondrelle S; Padgett K; van der Leij F; van Lier A; Jurgenliemk-Schulz I. doi: 10.3389/fonc.2021.628131.
Adaptive Radiotherapy in the Management of Cervical Cancer: Review of Strategies and Clinical Implementation.
Clin Oncol (R Coll Radiol). 2021;33:579-590. Shelley CE; Barraclough LH; Nelder CL; Otter SJ; Stewart AJ. doi: 10.1016/j.clon.2021.06.007.
Realizing the potential of magnetic resonance image guided radiotherapy in gynaecological and rectal cancer.
Br J Radiol. 2019;92:20180670. White IM; Scurr E; Wetscherek A; Brown G; Sohaib A; Nill S; Oelfke U; Dearnaley D; Lalondrelle S; Bhide S. doi: 10.1259/bjr.20180670.
The Potential Value of MRI in External-Beam Radiotherapy for Cervical Cancer.
Clin Oncol (R Coll Radiol). 2018;30:737-750. Cree A; Livsey J; Barraclough L; Dubec M; Hambrock T; Van Herk M; Choudhury A; McWilliam A. doi: 10.1016/j.clon.2018.08.002.
Head and Neck
Individual elective lymph node irradiation for the reduction of complications in head and neck cancer patients (iNode): A phase-I feasibility trial protocol.
Clin Transl Radiat Oncol. 2023;39:100574-100574. Reinders FCJ; de Ridder M; Doornaert PAH; P J Raaijmakers C; Philippens MEP. doi: 10.1016/j.ctro.2022.100574.
MR-Guided Adaptive Radiotherapy for OAR Sparing in Head and Neck Cancers.
Cancers (Basel). 2022;14:1909. Mulder SL; Heukelom J; McDonald BA; Van Dijk L; Wahid KA; Sanders K; Salzillo TC; Hemmati M; Schaefer A; Fuller CD. doi: 10.3390/cancers14081909.
Magnetic Resonance-Guided Radiation Therapy for Head and Neck Cancers.
Curr Oncol. 2022;29:8302-8315. Lavigne D; Ng SP; O'Sullivan B; Nguyen-Tan PF; Filion E; Létourneau-Guillon L; Fuller CD; Bahig H. doi: 10.3390/curroncol29110655.
Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study.
Int J Radiat Oncol Biol Phys. 2022;113:426-436. Cardenas CE; Blinde SE; Mohamed ASR; Ng SP; Raaijmakers C; Philippens M; Kotte A; Al-Mamgani AA; Karam I; Thomson DJ; Robbins J; Newbold K; Fuller CD; Terhaard C. doi: 10.1016/j.ijrobp.2022.01.050.
The impact of gadolinium-based MR contrast on radiotherapy planning for oropharyngeal treatment on the MR Linac.
Med Phys. 2022;49:510-520. Hales RB; Chuter R; McWilliam A; Salah A; Dubec M; Freear L; McDaid L; Aznar M; van Herk M; McPartlin A; Eccles CL. doi: 10.1002/mp.15325.
MR-Guided Radiotherapy for Head and Neck Cancer: Current Developments, Perspectives, and Challenges.
Front Oncol. 2021;11:616156. Boeke S; Monnich D; van Timmeren JE; Balermpas P. doi: 10.3389/fonc.2021.616156.
Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.
Int J Radiat Oncol Biol Phys. 2021;111:867-875. Christodouleas JP; Blezer ELA; Akhiat H; Brown K; Choudhury A; Eggert D; Erickson BA; Daamen LA; Faivre-Finn C; Fuller CD; Goldwein J; Hafeez S; Hall E; Harrington KJ; van der Heide UA; Huddart RA; Intven MPW; Kirby AM; Lalondrelle S; McCann C; Minsky BD; Mook S; Nowee ME; Oelfke U; Orrling K; Philippens MEP; Sahgal A; Schultz CJ; Tersteeg RJHA; Tijssen RHN; Tree AC; van Triest B; Tseng CL; Hall WA; Verkooijen HM; de_Mol_van_Otterloo SR. doi: 10.1016/j.ijrobp.2021.07.003.
Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation.
Int J Radiat Oncol Biol Phys. 2021;109:1606-1618. McDonald BA; Vedam S; Yang J; Wang J; Castillo P; Lee B; Sobremonte A; Ahmed S; Ding Y; Mohamed ASR; Balter P; Hughes N; Thorwarth D; Nachbar M; Philippens MEP; Terhaard CHJ; Zips D; Böke S; Awan MJ; Christodouleas J; Fuller CD. doi: 10.1016/j.ijrobp.2020.12.015.
Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial.
Clin Transl Radiat Oncol. 2018;13:19-23. Bahig H; Yuan Y; Mohamed ASR; Brock KK; Ng SP; Wang J; Ding Y; Hutcheson K; McCulloch M; Balter PA; Lai SY; Al-Mamgani A; Sonke JJ; van der Heide UA; Nutting C; Li XA; Robbins J; Awan M; Karam I; Newbold K; Harrington K; Oelfke U; Bhide S; Philippens MEP; Terhaard CHJ; McPartlin AJ; Blanchard P; Garden AS; Rosenthal DI; Gunn GB; Phan J; Cazoulat G; Aristophanous M; McSpadden KK; Garcia JA; van den Berg CAT; Raaijmakers CPJ; Kerkmeijer L; Doornaert P; Blinde S; Frank SJ; Fuller CD. doi: 10.1016/j.ctro.2018.08.003.
The Use of MR-Guided Radiation Therapy for Head and Neck Cancer and Recommended Reporting Guidance.
Semin Radiat Oncol. 2024;34:69-83. McDonald BA; Dal Bello R; Fuller CD; Balermpas P. doi: 10.1016/j.semradonc.2023.10.003.
MR-guided stereotactic radiation therapy for head and neck cancers
Clin Transl Radiat Oncol. 2024;46:100760. Wang H; Yang J; Lee A; Phan J; Lim T; Fuller C; Han E; Rhee D; Salzillo T; Zhao Y; Chopra N; Pham M; Castillo P; Sobremonte A; Moreno A; Reddy J; Rosenthal D; Garden A; Wang X. doi: 10.1016/j.ctro.2024.100760.
Heart
MR-Linac guided adaptive stereotactic ablative body radiotherapy for recurrent cardiac sarcoma with mitral valve bioprosthesis - a case report.
J Med Radiat Sci. 2023;70:199-205. Batumalai V; Carr M; Jameson M; Crawford D; Jelen U; Pagulayan C; Twentyman T; Hong A; de Leon J. doi: 10.1002/jmrs.669.
Cardiac angiosarcoma treated with 1.5 Tesla MR-guided adaptive stereotactic body radiotherapy - Case report and review of the literature.
Int J Surg Case Rep. 2022;98:107521. Noyan A; Yavas G; Efe E; Arslan G; Yavas C; Onal C. doi: 10.1016/j.ijscr.2022.107521.
Sarcoma of the Heart Treated with Stereotactic MR-Guided Online Adaptive Radiation Therapy.
Case Rep Oncol. 2021;14:453-458. Pomp J; van Asselen B; Tersteeg RHA; Vink A; Hassink RJ; van der Kaaij NP; van Aarnhem GEEHL; Verhoeff JJC. doi: 10.1159/000513623.
Oligomets
Intra-fraction motion of pelvic oligometastases and feasibility of PTV margin reduction using MRI guided adaptive radiotherapy.
Front Oncol. 2023;13:1098593. Snyder J; Smith B; St-Aubin J; Dunkerley D; Shepard A; Caster J; Hyer D. doi: 10.3389/fonc.2023.1098593.
1.5 T MR-Guided Daily Adapted SBRT on Lymph Node Oligometastases from Prostate Cancer.
J Clin Med. 2022;11:6658. Nicosia L; Trapani G; Rigo M; Giaj-Levra N; Mazzola R; Pastorello E; Ricchetti F; Cuccia F; Figlia V; Fiorini M; Alongi F. doi: 10.3390/jcm11226658.
Impact of magnetic resonance-guided versus conventional radiotherapy workflows on organ at risk doses in stereotactic body radiotherapy for lymph node oligometastases.
Phys Imaging Radiat Oncol. 2022;23:66-73. Werensteijn-Honingh AM; Kroon PS; Winkel D; van Gaal JC; Hes J; Snoeren LMW; Timmer JK; Mout CCP; Bol GH; Kotte AN; Eppinga WSC; Intven M; Raaymakers BW; Jürgenliemk-Schulz IM. doi: 10.1016/j.phro.2022.06.011.
Impact of a vacuum cushion on intrafraction motion during online adaptive MR-guided SBRT for pelvic and para-aortic lymph node oligometastases.
Radiother Oncol. 2021;154:110-117. Werensteijn-Honingh AM; Jurgenliemk-Schulz IM; Gadellaa-Van Hooijdonk CG; Sikkes GG; Vissers NGPM; Winkel D; Eppinga WSC; Intven M; Raaymakers BW; Kroon PS. doi: 10.1016/j.radonc.2020.09.021.
Dosimetric feasibility of hypofractionation for SBRT treatment of lymph node oligometastases on the 1.5T MR-linac.
Radiother Oncol. 2021;154:243-248. Winkel D; Werensteijn-Honingh AM; Eppinga WSC; Intven MPW; Hes J; Snoeren LMW; Visser SA; Bol GH; Raaymakers BW; Jürgenliemk-Schulz IM; Kroon PS. doi: 10.1016/j.radonc.2020.09.020.
Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment.
Radiother Oncol. 2020;146:118-125. Winkel D; Bol GH; Werensteijn-Honingh AM; Intven MPW; Eppinga WSC; Hes J; Snoeren LMW; Sikkes GG; Gadellaa-van Hooijdonk CGM; Raaymakers BW; Jurgenliemk-Schulz IM; Kroon PS. doi: 10.1016/j.radonc.2020.02.011.
Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases.
Radiother Oncol. 2019;134:50-54. Werensteijn-Honingh AM; Kroon PS; Winkel D; Aalbers EM; van Asselen B; Bol GH; Brown KJ; Eppinga WSC; van Es CA; Glitzner M; de Groot-van Breugel EN; Hackett SL; Intven M; Kok JGM; Kontaxis C; Kotte AN; Lagendijk JJW; Philippens MEP; Tijssen RHN; Wolthaus JWH; Woodings SJ; Raaymakers BW; Jurgenliemk-Schulz IM. doi: 10.1016/j.radonc.2019.01.024.
MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters.
Radiother Oncol. 2024;192:110090. van Overeem Felter M; Møller PK; Josipovic M; Bekke SN; Bernchou U; Serup-Hansen E; Madsen K; Parikh PJ; Kim J; Geertsen P; Behrens CP; Vogelius IR; Pøhl M; Schytte T; Persson GF. doi: 10.1016/j.radonc.2024.110090.
Practical considerations for the treatment of an adrenal metastasis with stereotactic body radiotherapy.
Pract Radiat Oncol. 2024;24:. Yu JB; Grew DJ; Sculley E; Hitchcock K; Kim M; Lo SS. doi: 10.1016/j.prro.2024.02.003.
Prostate
Development of prostate bed delineation consensus guidelines for MRI-guided radiotherapy and assessment of its impact on interobserver variability.
Int J Radiat Oncol Biol Phys. 2023;24. Sritharan K; Akhiat A; Cahill D; Choi S; Choudhury A; Chung P; Diaz J; Dysager L; Hall W; Huddart R; Kerkmeijer LGW; Lawton C; Mohajer J; Murray J; Nyborg CJ; Pos FJ; Rigo M; Schytte T; Sidhom M; Sohaib A; Tan A; van der Voort van Zyp J; Vesprini D; Zelefsky MJ; Tree AC. doi: 10.1016/j.ijrobp.2023.08.051.
Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability.
Radiol Med. 2023;128:612-618. Nicosia L; Mazzola R; Rigo M; Giaj-Levra N; Pastorello E; Ricchetti F; Vitale C; Figlia V; Cuccia F; Ruggieri R; Alongi F. doi: 10.1007/s11547-023-01624-7.
SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: An analysis of the dosimetric impact of intra-fractional organ changes.
Radiother Oncol. 2023;179:109441. Brennan VS; Burleson S; Kostrzewa C; Godoy Scripes P; Subashi E; Zhang Z; Tyagi N; Zelefsky MJ. doi: 10.1016/j.radonc.2022.109441.
Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer.
J Cancer Res Clin Oncol. 2023;149:841-850. Poon DMC; Yang B; Geng H; Wong OL; Chiu ST; Cheung KY; Yu SK; Chiu G; Yuan J. doi: 10.1007/s00432-022-03950-1.
Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac.
Front Oncol. 2023;13:1039901. Gao LR; Tian Y; Wang MS; Xia WL; Qin SR; Song YW; Wang SL; Tang Y; Fang H; Tang Y; Qi SN; Yan LL; Liu YP; Jing H; Chen B; Xing NZ; Li YX; Lu NN. doi: 10.3389/fonc.2023.1039901.
Advances in erectile function-preserving radiotherapy for prostate cancer.
J Sex Med. 2023;20:121-123. Teunissen FR; van der Voort van Zyp JRN; Wortel RC. doi: 10.1093/jsxmed/qdac015.
Magnetic Resonance-Guided Adaptive Radiation therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy.
Pract Radiat Oncol. 2022;13(3):e261-e269. Teunissen FR; Willigenburg T; Tree AC; Hall WA; Choi SL; Choudhury A; Christodouleas JP; de Boer JCJ; Groot-van Breugel EN; Kerkmeijer LGW; Pos FJ; Schytte T; Vesprini D; Verkooijen HM; Voort van Zyp JRNV. doi: 10.1016/j.prro.2022.09.007.
1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients.
J Pers Med. 2022;12:1982. Alongi F; Rigo M; Figlia V; Nicosia L; Mazzola R; Giaj Levra N; Ricchetti F; Trapani G; Attinà G; Vitale C; Pastorello E; De Simone A; Gurrera D; Naccarato S; Sicignano G; Ruggieri R; Cuccia F. doi: 10.3390/jpm12121982.
Daily online contouring and re-planning versus translation-only correction in neurovascular-sparing magnetic resonance-guided radiotherapy for localized prostate cancer.
Phys Imaging Radiat Oncol. 2022;24:43-46. Teunissen FR; van der Voort van Zyp JRN; de Groot-van Breugel EN; Verkooijen HM; Wortel RC; de Boer JCJ. doi: 10.1016/j.phro.2022.09.002.
Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology.
Front Oncol. 2022;12:962897. Hall WA; Kishan AU; Hall E; Nagar H; Vesprini D; Paulson E; Van der Heide UA; Lawton CAF; Kerkmeijer LGW; Tree AC. doi: 10.3389/fonc.2022.962897.
First Experience and Prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in Patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac.
J Clin Med. 2022;11. Wegener D; Thome A; Paulsen F; Gani C; Boldt J; Butzer S; Thorwarth D; Moennich D; Nachbar M; Müller AC; Zips D; Boeke S. doi: 10.3390/jcm11164651.
A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.
Cancers (Basel). 2022;14:3484. Poon DMC; Yuan J; Yang B; Wong OL; Chiu ST; Chiu G; Cheung KY; Yu SK; Yung RWH. doi: 10.3390/cancers14143484.
Vas deferens metastasis from prostate adenocarcinoma treated with daily-adaptive MR-guided SBRT on 1.5T MR-linac.
Rep Pract Oncol Radiother. 2022;27:371-374. Vitale C; Nicosia L; Pastorello E; Rigo M; Doraku J; Salgarello M; Alongi F. doi: 10.5603/RPOR.a2022.0035.
Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver.
Front Oncol. 2022;12:877452. Li W; Winter J; Padayachee J; Dang J; Kong V; Chung P. doi: 10.3389/fonc.2022.877452.
Clinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy.
Front Oncol. 2022;12:909402. Turkkan G; Bilici N; Sertel H; Keskus Y; Alkaya S; Tavli B; Ozkirim M; Fayda M. doi: 10.3389/fonc.2022.909402.
1.5T MR-Guided Daily Adaptive Stereotactic Body Radiotherapy for Prostate Re-Irradiation: A Preliminary Report of Toxicity and Clinical Outcomes.
Front Oncol. 2022;12:858740. Cuccia F; Rigo M; Figlia V; Giaj-Levra N; Mazzola R; Nicosia L; Ricchetti F; Trapani G; De Simone A; Gurrera D; Naccarato S; Sicignano G; Ruggieri R; Alongi F. doi: 10.3389/fonc.2022.858740.
Case Report: Adaptive radiotherapy in the radiation salvage of prostate cancer.
Front Oncol. 2022;12:898822. Montalvo SK; Meng B; Lin MH; Park C; Desai NB; Hannan R; Garant A. doi: 10.3389/fonc.2022.898822.
The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating 'trials within cohorts' (TwiCs) for the evaluation of interventions for prostate cancer.
World J Urol. 2022;40(9):2205-2212. Teunissen FR; Willigenburg T; Meijer RP; van Melick HHE; Verkooijen HM; van der Voort van Zyp JRN. doi: 10.1007/s00345-022-04092-2.
Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy.
Radiother Oncol. 2022;171:182-188. Willigenburg T; van der Velden JM; Zachiu C; Teunissen FR; Lagendijk JJW; Raaymakers BW; de Boer JCJ; van der Voort van Zyp JRN. doi: 10.1016/j.radonc.2022.04.022.
Prostate Volume Changes during Extreme and Moderately Hypofractionated Magnetic Resonance Image-guided Radiotherapy.
Clin Oncol . 2022;34(9):e383-e391. Alexander SE; McNair HA; Oelfke U; Huddart R; Murray J; Pathmanathan A; Patel P; Sritharan K; van As N; Tree AC. doi: 10.1016/j.clon.2022.03.022.
HERMES: Delivery of a Speedy Prostate Cancer Treatment.
Clin Oncol . 2022;34(7):426-429. Westley R; Hall E; Tree A. doi: 10.1016/j.clon.2022.01.003.
Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.
Int J Radiat Oncol Biol Phys. 2021;111:867-875. Christodouleas JP; Blezer ELA; Akhiat H; Brown K; Choudhury A; Eggert D; Erickson BA; Daamen LA; Faivre-Finn C; Fuller CD; Goldwein J; Hafeez S; Hall E; Harrington KJ; van der Heide UA; Huddart RA; Intven MPW; Kirby AM; Lalondrelle S; McCann C; Minsky BD; Mook S; Nowee ME; Oelfke U; Orrling K; Philippens MEP; Sahgal A; Schultz CJ; Tersteeg RJHA; Tijssen RHN; Tree AC; van Triest B; Tseng CL; Hall WA; Verkooijen HM; de_Mol_van_Otterloo SR. doi: 10.1016/j.ijrobp.2021.07.003.
Seminal vesicle intrafraction motion during the delivery of radiotherapy sessions on a 1.5 T MR-Linac.
Radiother Oncol. 2021;162:162-169. Muinck Keizer DM de; Willigenburg T; der Voort van Zyp JRN van; Raaymakers BW; Lagendijk JJW; Boer JCJ de. doi: 10.1016/j.radonc.2021.07.014.
1.5T Magnetic Resonance-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Preliminary Clinical Results of Clinician- and Patient-Reported Outcomes.
Cancers (Basel). 2021;13:4866. Poon DMC; Yuan J; Wong OL; Yang B; Chiu ST; Cheung KY; Chiu G; Yu SK. doi: 10.3390/cancers13194866.
Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes.
Radiol Med. 2021;126:989-997. Mazzola R; Cuccia F; Figlia V; Rigo M; Nicosia L; Giaj-Levra N; Ricchetti F; Vitale C; Mantoan B; Di Paola G; De Simone A; Gurrera D; Sicignano G; Naccarato S; Ruggieri R; Alongi F. doi: 10.1007/s11547-021-01352-w.
The impact of image acquisition time on registration, delineation and image quality for magnetic resonance guided radiotherapy of prostate cancer patients.
Phys Imaging Radiat Oncol. 2021;19:85-89. Nowee ME; van Pelt VWJ; Walraven I; Simoes R; Liskamp CP; Lambregts DMJ; Heijmink S; Schaake E; van der Heide UA; Janssen TM. doi: 10.1016/j.phro.2021.07.002.
Development of patient-reported outcomes item set to evaluate acute treatment toxicity to pelvic online magnetic resonance-guided radiotherapy.
J Patient Rep Outcomes. 2021;5:47. Moller PK; Pappot H; Bernchou U; Schytte T; Dieperink KB. doi: 10.1186/s41687-021-00326-w.
An unusual case of oedematous prostate volumetric changes observed over the course of radiotherapy on the MR linear accelerator.
J Med Imaging Radiat Sci. 2021;52:147-151. Clough A; Bridge P; Hales R; McDaid L; Choudhury A; Eccles CL. doi: 10.1016/j.jmir.2020.11.019.
Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes.
Br J Radiol. 2021;94:20200848. Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R. doi: 10.1259/bjr.20200848.
Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer.
Br J Radiol. 2021;94:20210521. Mazzola R; Sicignano G; Cuccia F; Vitale C; Rigo M; Giaj-Levra N; Nicosia L; Figlia V; Ricchetti F; Attina G; Pastorello E; De Simone A; Gurrera D; Naccarato S; Ruggieri R; Alongi F. doi: 10.1259/bjr.20210521.
Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac.
Radiother Oncol. 2020;151:88-94. de Muinck Keizer DM; Kerkmeijer LGW; Willigenburg T; van Lier ALHMW; Hartogh MDD; van der Voort van Zyp JRN; de Groot-van Breugel EN; Raaymakers BW; Lagendijk JJW; de Boer JCJ. doi: 10.1016/j.radonc.2020.06.044.
Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes.
J Cancer Res Clin Oncol. 2020;146:2379-2397. Mazzola R; Figlia V; Rigo M; Cuccia F; Ricchetti F; Giaj-Levra N; Nicosia L; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Alongi F. doi: 10.1007/s00432-020-03230-w.
Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.
Radiat Oncol. 2020;15:178. Cuccia F; Mazzola R; Nicosia L; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Mantoan B; De Simone A; Sicignano G; Ruggieri R; Cavalleri S; Alongi F. doi: 10.1186/s13014-020-01622-3.
1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Radiat Oncol. 2020;15:69. Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R. doi: 10.1186/s13014-020-01510-w.
Prostate cancer - Advantages and disadvantages of MR-guided RT.
Clin Transl Radiat Oncol. 2019;18:68-73. Murray J; Tree AC. doi: 10.1016/j.ctro.2019.03.006.
First clinical experiences with a high field 1.5 T MR linac.
Acta Oncol. 2019;58:1352-1357. Bertelsen AS; Schytte T; Moller PK; Mahmood F; Riis HL; Gottlieb KL; Agergaard SN; Dysager L; Hansen O; Gornitzka J; Veldhuizen E; ODwyer DB; Christiansen RL; Nielsen M; Jensen HR; Brink C; Bernchou U. doi: 10.1080/0284186X.2019.1627417.
Interim toxicity analysis from the randomised HERMES trial of 2- and 5-fraction MRI-guided adaptive prostate radiotherapy.
Int J Radiat Oncol Biol Phys. 2023;118(3):682-687. Westley DRL; Biscombe K; Dunlop A; Mitchell A; Oelfke U; Nil S; Murray J; Pathmanathan A; Hafeez S; Parker C; Ratnakumaran R; Alexander S; Herbert T; Hall E; Tree AC. doi: 10.1016/j.ijrobp.2023.09.032.
Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity.
Radiother Oncol. 2024;190:110043. Nicosia L; Ravelli P; Rigo M; Giaj-Levra N; Mazzola R; Pastorello E; Ricchetti F; Allegra AG; Ruggieri R; Alongi F. doi: 10.1016/j.radonc.2023.110043.
MRI-Guided Radiotherapy for Prostate Cancer: Seeing is Believing.
Semin Radiat Oncol. 2024;34:45-55. Westley RL; Valle LF; Tree AC; Kishan AU. doi: 10.1016/j.semradonc.2023.10.001.
MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study
Clin Transl Radiat Oncol. 2024;46:100742. Sritharan K; Daamen L; Pathmanathan A; Schytte T; Pos F; Choudhury A; van der Voort van Zyp J; Kerkmeijer L; Hall W; Hall E; Verkooijen H; Herbert T; Hafeez S; Mitchell A; Tree A. doi: 10.1016/j.ctro.2024.100742.
Magnetic resonance guided adaptive post prostatectomy radiotherapy: Accumulated dose comparison of different workflows.
J Appl Clin Med Phys. 2024;25 (4):e14253. Hassan SP; de Leon J; Batumalai V; Moutrie Z; Hogan L; Ge Y; Stricker P; Jameson MG. doi: 10.1002/acm2.14253.
One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer.
World J Urol. 2024;42:97. Poon DMC; Yuan J; Wong OL; Yang B; Tse MY; Lau KK; Chiu ST; Chiu PK; Ng CF; Chui KL; Kwong YM; Ma WK; Cheung KY; Chiu G; Yu SK. doi: 10.1007/s00345-024-04784-x.
Rectum
Effectiveness of bladder filling control during online MR-guided adaptive radiotherapy for rectal cancer.
Radiat Oncol. 2023;18:136. Feng X; Tang B; Yao X; Liu M; Liao X; Yuan K; Peng Q; Orlandini LC. doi: 10.1186/s13014-023-02315-3.
Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
BMJ Open. 2023;13:e065010. Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP. doi: 10.1136/bmjopen-2022-065010.
Impact of endorectal filling on interobserver variability of MRI based rectal primary tumor delineation.
Clin Transl Radiat Oncol. 2023;38:1-5. Lo Russo M; Nachbar M; Barry A; Bhide S; Chang A; Hall W; Intven M; Marijnen C; Peters F; Minsky B; Romesser PB; Sarkar R; Tan A; Boeke S; Wegener D; Butzer S; Boldt J; Gatidis S; Nikolaou K; Thorwarth D; Zips D; Gani C. doi: 10.1016/j.ctro.2022.09.002.
Online Adaptive MRI-Guided Radiotherapy for Primary Tumor and Lymph Node Boosting in Rectal Cancer.
Cancers (Basel). 2023;15:1009. Kensen CM; Betgen A; Wiersema L; Peters FP; Kayembe MT; Marijnen CAM; van der Heide UA; Janssen TM. doi: 10.3390/cancers15041009.
Quantitative analysis of diffusion weighted imaging in rectal cancer during radiotherapy using a magnetic resonance imaging integrated linear accelerator.
Phys Imaging Radiat Oncol. 2022;23:32-37. Ingle M; Blackledge M; White I; Wetscherek A; Lalondrelle S; Hafeez S; Bhide S. doi: 10.1016/j.phro.2022.06.003.
Online MR guided dose escalated radiotherapy for organ preservation in distal rectal cancer.
Clin Transl Radiat Oncol. 2022;37:153-156. Boeke S; Uder L; Ehlers J; Butzer S; Baumeister S; Boldt J; Nachbar M; Lo Russo M; Mönnich D; Nikolaou K; Zips D; Thorwarth D; Gani C. doi: 10.1016/j.ctro.2022.10.003.
Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac: clinical implementation and initial experience.
Radiother Oncol. 2021;154:172-178. Intven MPW; de Mol van Otterloo SR; Mook S; Doornaert PAH; de Groot-van Breugel EN; Sikkes GG; Willemsen-Bosman ME; van Zijp HM; Tijssen RHN. doi: 10.1016/j.radonc.2020.09.024.
MR-Guided Radiotherapy for Rectal Cancer: Current Perspective on Organ Preservation.
Front Oncol. 2021;11:619852. Boldrini L; Intven M; Bassetti M; Valentini V; Gani C. doi: 10.3389/fonc.2021.619852.
A novel approach for radiotherapy dose escalation in rectal cancer using online MR-guidance and rectal ultrasound gel filling - Rationale and first in human.
Radiother Oncol. 2021;164:37-42. Gani C; Lo Russo M; Boeke S; Wegener D; Gatidis S; Butzer S; Boldt J; Mönnich D; Thorwarth D; Nikolaou K; Zips D; Nachbar M. doi: 10.1016/j.radonc.2021.09.002.
Interobserver variability in target volume delineation for CT/MRI simulation and MRI guided adaptive radiotherapy in rectal cancer.
Br J Radiol. 2021;94:20210350. White I; Hunt A; Bird T; Settatree S; Soliman H; Mcquaid D; Dearnaley D; Lalondrelle S; Bhide S. doi: 10.1259/bjr.20210350.
Realizing the potential of magnetic resonance image guided radiotherapy in gynaecological and rectal cancer.
Br J Radiol. 2019;92:20180670. White IM; Scurr E; Wetscherek A; Brown G; Sohaib A; Nill S; Oelfke U; Dearnaley D; Lalondrelle S; Bhide S. doi: 10.1259/bjr.20180670.
Rectal Cancer MRI Guided Radiotherapy: A Practical Review for the Physician.
Semin Radiat Oncol. 2024;34:64-68. Chiloiro G; Gani C; Boldrini L. doi: 10.1016/j.semradonc.2023.10.004.
Quality of life and clinical outcomes in rectal cancer patients treated on a 1.5T MR-Linac within the MOMENTUM study
Clin Transl Radiat Oncol. 2024;45:100721. Daamen L; Westerhoff J; Couwenberg A; Braam P; Rütten H; den Hartogh M; Christodouleas J; Hall W; Verkooijen H; Intven M. doi: 10.1016/j.ctro.2023.100721.
Thorax - Lung
Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial.
Radiat Oncol. 2023;18:74. Regnery S; de Colle C; Eze C; Corradini S; Thieke C; Sedlaczek O; Schlemmer HP; Dinkel J; Seith F; Kopp-Schneider A; Gillmann C; Renkamp CK; Landry G; Thorwarth D; Zips D; Belka C; Jäkel O; Debus J; Hörner-Rieber J. doi: 10.1186/s13014-023-02258-9.
Towards mid-position based Stereotactic Body Radiation Therapy using online magnetic resonance imaging guidance for central lung tumours.
Phys Imaging Radiat Oncol. 2022;23:24-31. Ligtenberg H; Hackett SL; Merckel LG; Snoeren L; Kontaxis C; Zachiu C; Bol GH; Verhoeff JJC; Fast MF. doi: 10.1016/j.phro.2022.05.002.
First experimental demonstration of VMAT combined with MLC tracking for single and multi fraction lung SBRT on an MR-linac.
Radiother Oncol. 2022;174:149-157. Uijtewaal P; Borman PTS; Woodhead PL; Kontaxis C; Hackett SL; Verhoeff J; Raaymakers BW; Fast MF. doi: 10.1016/j.radonc.2022.07.004.
Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer.
Front Oncol. 2021;11:617681. Crockett CB; Samson P; Chuter R; Dubec M; Faivre-Finn C; Green OL; Hackett SL; McDonald F; Robinson C; Shiarli AM; Straza MW; Verhoeff JJC; Werner-Wasik M; Vlacich G; Cobben D. doi: 10.3389/fonc.2021.617681.
Magnetic resonance imaging in precision radiation therapy for lung cancer.
Transl Lung Cancer Res. 2017;6:689-707. Bainbridge H; Salem A; Tijssen RHN; Dubec M; Wetscherek A; Van Es C; Belderbos J; Faivre-Finn C; McDonald F. doi: 10.21037/tlcr.2017.09.02.
MRI-guided lung SBRT: Present and future developments.
Phys Med. 2017;44:139-149. Menten MJ; Wetscherek A; Fast MF. doi: 10.1016/j.ejmp.2017.02.003.
Exploring the Advantages and Challenges of MR-Guided Radiotherapy in Non-Small-Cell Lung Cancer: Who are the Optimal Candidates?
Semin Radiat Oncol. 2024;34:56-63. Wu TC; Smith LM; Woolf D; Faivre-Finn C; Lee P. doi: 10.1016/j.semradonc.2023.10.007.
Stereotactic Body Radiotherapy of Central Lung Tumours using a 1.5T MR-linac: first clinical experiences
Clin Transl Radiat Oncol. 2024;45:100744. Merckel L.G.; Pomp J.; Hackett S.L.; van Lier A.; van den Dobbelsteen M.; RasingM.J.A.; Mohamed HoeseinF.A.A.; SnoerenL.M.W.; van Es C.A.; van RossumP.S.N.; Fast M.F.; VerhoeffJ.J.C.. doi: 10.1016/j.ctro.2024.100744.
Other
Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma.
Front Oncol. 2021;11:634830. Keller B; Bruynzeel AME; Tang C; Swaminath A; Kerkmeijer L; Chu W. doi: 10.3389/fonc.2021.634830.
Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy.
Front Oncol. 2022;12:962926-962926. Kozak MM; Crompton D; Gross BA; Harshman L; Dickens D; Snyder J; Shepard A; St-Aubin J; Dunkerley D; Hyer D; Buatti JM. doi: 10.3389/fonc.2022.962926.
The potential role of MR-guided adaptive radiotherapy in pediatric oncology: Results from a SIOPE-COG survey.
Clin Transl Radiat Oncol. 2021;29:71-78. Seravalli E; Kroon PS; Buatti JM; Hall MD; Mandeville HC; Marcus KJ; Onal C; Ozyar E; Paulino AC; Paulsen F; Saunders D; Tsang DS; Wolden SL; Janssens GO. doi: 10.1016/j.ctro.2021.05.008.
Reassessing the Role of Radiation Therapy for the Treatment of Lymphoma: Historical Perspective and Opportunities in the Era of Image-Guided and Adaptive Radiation Therapy.
J Oncol Pract. 2019;15:175-176. Schultz CJ. doi: 10.1200/JOP.19.00146.
Impact of abdominal compression on intra-fractional motion and delivered dose in magnetic resonance image-guided adaptive radiation ablation of adrenal gland metastases.
Phys Med. 2023;114:102682. Bernchou U; Schytte T; Bertelsen A; Lorenzen EL; Brink C; Mahmood F. doi: 10.1016/j.ejmp.2023.102682.
Case report: Stereotactic MR-guided adaptive radiotherapy for inoperable urothelial carcinoma at the renal pelvis
Front Oncol.. 2024;8:1284417. Thaweerat W; Dankulchai P. doi: 10.3389/fonc.2023.1284417.